Featured Articles

Roche announced that the U.S. Food and Drug Administration (FDA) has accepted, under Priority Review, the company’s supplemental Biologics License Application (sBLA) for Xolair…
Read More...

Merck, known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration (FDA) has accepted for priority review a new Biologics License Application…
Read More...

Teva Pharmaceutical Industries Ltd. and Biolojic Design Ltd. ("Biolojic"), a biotechnology company that uses computational biology and artificial intelligence to transform antibodies…
Read More...

Alkermes plc announced that it has entered into a definitive agreement to sell its development and manufacturing facility in Athlone, Ireland to Novo Nordisk, a leading global…
Read More...

Almirall, S.A. (ALM), a global pharmaceutical company focused on medical dermatology, and etherna, an mRNA/LNP technology platform company, announced a multi-target alliance to discover…
Read More...

AstraZeneca has entered into a definitive agreement to acquire Icosavax, Inc., a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential…
Read More...

Interactomics pioneer Depixus has entered a collaboration with Daiichi Sankyo to use their novel MAGNA technology to accelerate the Japanese healthcare leader’s RNA-targeted drug…
Read More...

Ipsen and GENFIT announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for investigational elafibranor. An oral, once-daily dual…
Read More...

Arvinas, Inc. and Pfizer Inc. announced clinical data for vepdegestrant (ARV-471), a novel oral PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in combination…
Read More...

Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. announced closing of its collaboration deal to co-develop and co-commercialize asset TEV ‘574 with Sanofi.…
Read More...

AbbVie Inc. and ImmunoGen, Inc. announced a definitive agreement under which AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE (mirvetuximab soravtansine-gynx), a…
Read More...

PRISM BioLab, Co. Ltd. announced that it has entered into a License and Collaboration Agreement with Eli Lilly and Company ("Lilly"). Under the agreement, PRISM and Lilly will…
Read More...

Boehringer Ingelheim and IBM announced an agreement that will enable Boehringer to use IBM’s foundation model technologies to discover novel candidate antibodies for the development…
Read More...

AbbVie announced updates from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for epcoritamab, an investigational T-cell engaging bispecific antibody…
Read More...

Boehringer Ingelheim announced the acquisition of privately-held T3 Pharmaceuticals AG (“T3 Pharma”), a clinical stage Swiss biotech company, for an amount of up to 450 million CHF.…
Read More...

Merck, known as MSD outside of the United States and Canada, and Caraway Therapeutics, Inc. announced that the companies have entered into a definitive agreement under which Merck,…
Read More...

Genentech, a member of the Roche Group announced a multi-year strategic research collaboration with NVIDIA that couples Genentech’s artificial intelligence (AI) capabilities, extensive…
Read More...

Astellas Pharma Inc. and Propella Therapeutics, Inc. announced that Astellas, through a US subsidiary, and Propella have entered into a merger agreement pursuant to which Astellas will…
Read More...

Almirall S.A., a global biopharmaceutical company focused on medical dermatology, and Absci Corporation, a generative AI drug creation company, announced a drug discovery partnership…
Read More...

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. and Royalty Pharma plc, announced a collaboration to further accelerate the clinical…
Read More...